

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 March 2024 (21.03.2024)



(10) International Publication Number
WO 2024/059317 A1

(51) International Patent Classification:

C07D 205/04 (2006.01)	C07D 417/06 (2006.01)
C07D 205/12 (2006.01)	C07D 471/04 (2006.01)
C07D 207/08 (2006.01)	C07D 491/10 (2006.01)
C07D 207/12 (2006.01)	A61K 31/397 (2006.01)
C07D 211/18 (2006.01)	A61K 31/40 (2006.01)
C07D 211/38 (2006.01)	A61K 31/403 (2006.01)
C07D 211/48 (2006.01)	A61K 31/427 (2006.01)
C07D 401/06 (2006.01)	A61K 31/45 (2006.01)
C07D 403/04 (2006.01)	A61K 31/422 (2006.01)
C07D 405/04 (2006.01)	A61K 31/427 (2006.01)
C07D 413/06 (2006.01)	A61P 35/00 (2006.01)
C07D 413/08 (2006.01)	

(21) International Application Number:

PCT/US2023/032957

(22) International Filing Date:

15 September 2023 (15.09.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/407,148 15 September 2022 (15.09.2022) US

(71) Applicant: **BRIDGENE BIOSCIENCES, INC.** [US/US];
75 Nicholson Lane, San Jose, California 95134 (US).

(72) Inventors: **JOHNSON, Henry William Beecroft**; c/o BridGene Biosciences, Inc., 75 Nicholson Lane, San Jose, California 95134 (US). **LUO, Zhushou**; c/o BridGene Biosciences, Inc., 75 Nicholson Lane, San Jose, California 95134 (US). **ZHANG, Chao**; c/o BridGene Biosciences, Inc., 75 Nicholson Lane, San Jose, California 95134 (US). **BISHOP, Michael J.**; c/o BridGene Biosciences, Inc., 75 Nicholson Lane, San Jose, California 95134 (US).

(74) Agent: **RICE, Janice V.** et al.; SQUIRE PATTON BOGGS (US) LLP, 555 California Street, Suite 550, San Francisco, California 94104 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: YAP/TAZ-TEAD ONCOPROTEINS INHIBITORS

(57) Abstract: Provided are YAP/TAZ-TEAD oncoproteins inhibitors of Formula (I), or a stereoisomer, and/or a pharmaceutically acceptable salt, and/or solvate thereof, pharmaceutical compositions thereof, and methods of treatment.

WO 2024/059317 A1